Pharmaceutical

Avricore Health’s HealthTab™ Platform Expands to North Central London in Groundbreaking NHS Pharmacy-Led Cardiovascular Project

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased...

Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

 - Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate...

Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal

Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profileRobust complementary immune...

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0),...

Pioneering alliance between The Jackson Laboratory and The New York Stem Cell Foundation ushers in new era of predictive biomedical research

Uniting cutting-edge genomics, stem cell science, and AI-enabled data science to accelerate the discovery of life-changing therapies BAR HARBOR, Maine...

Zhimeng Biopharma’s Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study

SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug...

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”),...

error: Content is protected !!